Bayer puts the brakes on vilaprisan trials following safety concerns
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.